Dermata Therapeutics (DRMA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Dermata Therapeutics Inc (DRMA)

Serving as the primary valuation tool, this Dermata Therapeutics (DRMA) price chart demonstrates an EV/EBITDA of 0.00. Dermata Therapeutics develops advanced treatments for severe acne using unique silicon for targeted delivery. However, the business faces intense pressure from industry behemoths and regulatory risks. Consequently, the firm is fighting to capture its niche before affordable alternatives emerge.

Dermata - DRMA Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

dermatarx.com - analytical breakdowns and key metrics (DRMA)

- market price and analyst price targets:
Price Chart Dermata|DRMA - Analyst Median Target
- market capitalization details:
Market Value Dermata Corp|DRMA - Enterprise Value
- book value of equity indicators:
Book Value per Share Dermata Therapeutics|DRMA - Book Valuation of Business|Market Value to Book Value Ratio dermatarx.com|DRMA - Total Business Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Dermata Therapeutics|DRMA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Dermata Therapeutics, Inc.|DRMA - Company Cumulative Debt|Debt to Book Capitalization Ratio Dermata Corp|DRMA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Dermata Therapeutics|Quick Ratio dermatarx.com
- financial results and valuation multiples details:
DRMA - Net Profit|Future Profit Dermata Therapeutics|DRMA - Market Price to Net Income Ratio|Forward P/E Multiple Dermata Therapeutics|DRMA - PEG Multiple|Enterprise Value to EBITDA Ratio Dermata Corp|DRMA - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Dermata Therapeutics|DRMA - Earnings per share for the last four quarters|Quarterly EPS earnings growth dermatarx.com|DRMA - Earnings per share increase in current year|Earnings growth forecast for next year Dermata Therapeutics
Initial company analysis:DRMA (Dermata)
Product sample of dermatarx.com

The multiple compares the total enterprise value, including net debt, to its operating profit before taxes and amortization. By analyzing the historical EV/EBITDA trajectory, an investor determines the extent of the premium paid for the asset relative to its ability to generate cash flow. For Dermata Therapeutics (DRMA), this valuation balance is critical as the company invests in retaining a unique staff of research dermatologists and developing innovative drugs.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Krystal Corp KRYS|Total Company Value to Operating Income Before Depreciation Ratio Apogee Corp (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Tech|Enterprise Value to Operating Income Before Depreciation SLSN (Solesence Inc.)|EV/EBITDA Multiple DERM|fortebiorx.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple EMPG (Empro Group)|Sol-Gel Technologies Ltd (SLGL) - Company Value to EBITDA|AXIL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation MDCX (Medicus Pharma Corp)|verrica.com (VRCA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Hoth Therapeutics|BFRI (Biofrontera, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple VYNE Therapeutics Inc|Enterprise Value to EBITDA Ratio SNOA (Sonoma Pharmaceuticals)|Enterprise Value to Operating Income Before Depreciation Ratio QNRX|EV/EBITDA Multiple AZTR (Azitra, Inc.)|EV/EBITDA Multiple elevaiskincare.com ELAB|RVNC: Enterprise Value to EBITDA Ratio